secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001104659-22-086174
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q2 revenue up 14% to $64.2M; net loss widens to $0.23/sh; guidance reaffirmed
--------------------------------------------------------------------------------

- Revenue $64.2M (+14% YoY, +18% constant currency); Biopharma/Pharma $51.7M (+14%).
- Net loss to common $11.2M ($0.23/sh) vs $7.4M ($0.16) in Q2 2021; GAAP net loss $9.2M.
- Adjusted EBITDA $6.0M, flat YoY; gross margin 45.0%, steady YoY and up 224bps sequentially.
- FY2022 revenue guidance reaffirmed at $260M-$265M; $33.3M share repurchase completed at avg $24.84.
- Record 626 clinical trials supported; opened new Global Supply Chain Centers; closed three acquisitions in Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922086174/0001104659-22-086174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922086174/tm2222628d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-086174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer